- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- CE-10-IVD
- Diagnostic Test
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 37
- States / cities
- San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 17,803
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older · Female only
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, placebo, liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 67
- States / cities
- Anaheim, California • Concord, California • Escondido, California + 59 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LGD-6972-5 mg, LGD-6972-10 mg, LGD-6972-15 mg, Placebo
- Drug · Other
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 29
- States / cities
- Tuscumbia, Alabama • Chandler, Arizona • Surprise, Arizona + 24 more
- Conditions
- Atopic Dermatitis
- Interventions
- Combination of pimecrolimus and fluticasone, pimecrolimus
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Chicago, Illinois • Houston, Texas
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- Palbociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
- Other · Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Triple Negative Breast Cancer
- Interventions
- BL-B01D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Duarte, California • Orange, California + 17 more
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 455
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more
- Conditions
- LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
- Interventions
- QLT091001
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Baltimore, Maryland
- Conditions
- Trauma Exposure, Trauma, Trauma and Stressor Related Disorder, Mental Health Functioning, Chronic Medical Conditions, Chronic Medical Condition, Chronic Medical Illness, Posttraumatic Stress Disorder PTSD, Posttraumatic Stress Disorders, Posttraumatic Stress Symptoms, Posttraumatic Stress
- Interventions
- Structured Psychotherapy for Adolescents Responding to Chronic Stress - Group, Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents - Group, Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents - Individual, Structured Psychotherapy for Adolescents Responding to Chronic Stress - Individual
- Behavioral
- Lead sponsor
- Anthony Vesco
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Withdrawal of anti-TNF therapy
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 4 Years to 20 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 16 Years · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 32 more
- Conditions
- Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Veliparib
- Radiation · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
- Conditions
- HSV Infection
- Interventions
- Pritelivir, Investigator's choice
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
- Conditions
- Heart Failure
- Interventions
- TEXT4HF
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
- Interventions
- sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,006 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 106
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more
- Conditions
- Invasive Mold Infections
- Interventions
- Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more
- Conditions
- HIV
- Interventions
- Evolution: Young Women Taking Charge and Growing Stronger
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 24 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Chicago, Illinois • Baltimore, Maryland
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver
- Interventions
- HepQuant
- Diagnostic Test
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Cancer, Lung Cancer
- Interventions
- celecoxib, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina
- Conditions
- Injury, Training
- Interventions
- Education
- Other
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alzheimer Disease
- Interventions
- xaliproden (SR57746A)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Anetumab Ravtansine, Bevacizumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 22
- States / cities
- Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more